報價延遲最少15分鐘:2026/01/22 05:33 EST
盤前時段
|
||||
|
-- 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
8
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.32/-0.73
|
|
企業價值
289.12M
|
| 資產負債 |
|
每股賬面淨值
0.89
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
10.68M
|
|
每股收益
0.18
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner. |
